1.
Shackley P. and Dixon S. (2013). The random card sort method and
respondent certainty in contingent valuation: an exploratory investigation of
range bias. Health Economics, DOI: 10.1002/hec.2980.
2.
Shackley P., Shaw L., Price C., van Wijck F., Barnes M., Graham L., Ford G.,
Steen N. and Rodgers H. (2012). Cost-effectiveness of treating upper limb
spasticity due to stroke with botulinum toxin type A: results from the
Botulinum Toxin for the Upper Limb after Stroke (BoTULS) trial. Toxins, 4(12),
1415-1426.
3.
Dixon S., Shackley P., Bonham J. and Ibbotson R. (2011). Putting a value on
the avoidance of false positive results when screening for inherited
metabolic diseases in the newborn. Journal of Inherited Metabolic Diseases,
DOI 10.1007/s10545-011-9354-0.
4.
Donaldson C., Baker R., Mason H., Jones-Lee M., Lancsar E., Wildman J.,
Bateman I., Loomes G., Robinson A., Sugden R., Pinto Prades J.L, Ryan M.,
Shackley P. and Smith R. (2011). The social value of a QALY: raising the bar
or barring the raise? BMC Health Services Research, 11(8).
5.
Shaw L., Rodgers H., Price C., van Wijck F., Shackley P., Steen N., Barnes M.,
Ford G., and Graham L. (2011). Botulinum Toxin for Upper Limb after Stroke
(BoTULS) Trial: effect upon impairment, activity limitations and pain. Stroke,
42, 1371-1379.
6.
Baker R., Bateman I., Donaldson C., Jones-Lee M., Lancsar E., Loomes G.,
Mason H., Odejar M., Pinto Prades J.L., Robinson A., Ryan M., Shackley P.,
Smith R., Sugden R. and Wildman J. (2010). Weighting and valuing quality
adjusted life years: preliminary results from the social value of a QALY
project. Health Technology Assessment, 14(27).
7.
Shaw L., Rodgers H., Price C., van Wijck F., Shackley P., Steen N., Barnes M.,
Ford G. and Graham L. (2010). BoTULS: a multi-centre randomised controlled
trial to evaluate the clinical and cost-effectiveness of treating upper limb
spasticity due to stroke with botulinum toxin type A. Health Technology
Assessment, 14(26).
8.
Michaels J.A., Campbell B., King B., Palfreyman S.J., Shackley P. and
Stevenson M. (2009). A randomised controlled trial and cost-effectiveness
analysis of silver donating antimicrobial dressings for venous leg ulcers: the
VULCAN trial. British Journal of Surgery, 96(10), 1147-1156.
9.
Michaels J.A., Campbell B., King B.M., MacIntyre J., Palfreyman S.J., Shackley
P., Stevenson M.D. (2009). A prospective randomised controlled trial and
economic modelling of antimicrobial silver dressings versus non-adherent
control dressings for venous leg ulcers: the VULCAN trial. Health Technology
Assessment, 13:56.
10.
Pennington M.W., Vernazza C.R., Shackley P., Armstrong N.T., Whitworth
J.M. and Steele J.G. (2009). Evaluation of the cost-effectiveness of root canal
treatment using conventional approaches versus replacement with an
implant. International Endodontics Journal, 42, 874-883.
11.
Rodgers H., Shaw L., Price P., van Wijck F., Barnes M., Graham L., Ford G.,
Shackley P. and Steen N., on behalf of the BoTULS investigators (2008).
Study design and methods of the BoTULS trial: a randomised controlled trial
to evaluate the clinical effect and cost effectiveness of treating upper limb
spasticity due to stroke with botulinum toxin type A. Trials, 9:59.
12.
Jameson K., Averley P.A., Shackley P. and Steele J. (2007). A comparison of
the ‘cost per child treated’ at a primary care based sedation referral service
compared to a general anaesthetic in hospital. British Dental Journal,
203(6):E13
13.
Marson A.G., Al-Kharusi A.M., Alwaidh M., Appleton R., Baker G.A., Chadwick
D.W., Cramp C., Cockerell O.C., Cooper P., Doughty J., Eaton B. , Gamble C.,
Goulding R.P., Howell S.J.L., Hughes A., Jackson M., Jacoby A.J., Kellett M.,
Lawson G.R., Leach J.P., Nicolaides P., Roberts R., Shackley P., Shen J., Smith
D.F., Smith P.E.M., Tudur-Smith C., Vanoli A., Williamson P.R. (2007). The
SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine,
oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded
randomised controlled trial. Lancet, 369, 1000-1015.
14.
Marson A.G., Al-Kharusi A.M., Alwaidh M., Appleton R., Baker G.A., Chadwick
D.W., Cramp C., Cockerell O.C., Cooper P., Doughty J., Eaton B. , Gamble C.,
Goulding R.P., Howell S.J.L., Hughes A., Jackson M., Jacoby A.J., Kellett M.,
Lawson G.R., Leach J.P., Nicolaides P., Roberts R., Shackley P., Shen J., Smith
D.F., Smith P.E.M., Tudur-Smith C., Vanoli A., Williamson P.R. (2007). The
SANAD study of effectiveness of valproate, lamotrigine, or topiramate for
generalised and unclassifiable epilepsy: an unblinded randomised controlled
trial. Lancet, 369, 1016-1026.
15.
Marson A.G., Appleton R., Baker G.A., Chadwick D.W., Doughty J., Eaton B.,
Gamble C., Jacoby A., Shackley P., Smith D.F., Tudur-Smith C., Vanoli A.,
Williamson P.R. (2007). A randomised controlled trial examining the longerterm outcomes of standard versus new antiepileptic drugs. The SANAD trial.
Health Technology Assessment, 11(37).
16.
Rubin G., Bate A., George A., Shackley P. and Hall N. (2006). Preferences for
access to the general practitioner: a discrete choice experiment. British
Journal of General Practice, 56, 743-748.
17.
Olsen J.A., Donaldson C. and Shackley P. (2005). Implicit versus explicit
ranking: on inferring ordinal preferences for health care programmes based
on differences in willingness to pay. Journal of Health Economics, 24, 990996.
18.
Olsen J.A., Kidholm K., Donaldson C. and Shackley P. (2004). Willingness to
pay for public health care: a comparison of two approaches. Health Policy,
70, 217-228.
19.
Protiere C., Donaldson C., Luchini S., Moatti J.P. and Shackley P. (2004). The
impact of information on non-health attributes on willingness to pay for
multiple health care programmes. Social Science and Medicine, 58, 12571269.
20.
Dixon S. and Shackley P. (2003). The use of willingness to pay to assess
public preferences toward the fortification of foodstuffs with folic acid:
results of a pilot study. Health Expectations, 6, 140-148.
21.
Zwierska I., Saxton J.M., Nawaz S., Wilkinson C.H., Walker R.D., Shackley P.,
Pockley A.G. and Wood R.F.M. (2003). Comparison of the shuttle-walk and
treadmill exercise tests for assessing patients with peripheral arterial
disease. British Journal of Surgery, 90(4), 502-503.
22.
Donaldson C and Shackley P. (2003). Willingness to Pay for Health Care.
Advances in Health Economics, 1 -24.
23.
Shackley P. and Donaldson C. (2002). Should we use willingness to pay to
elicit community preferences for health care? New evidence from using a
‘marginal’ approach. Journal of Health Economics, 21, 971-991.
24.
Stewart J., O’Shea E., Donaldson C. and Shackley P. (2002). Do ordering
effects matter in willingness to pay studies of health care? Journal of Health
Economics, 21(4), 585-599.
25.
Townend M. and Shackley P. (2002). Establishing and quantifying the
preferences of mental health service users for day hospital care: a pilot study
using conjoint analysis. Journal of Mental Health, 11(1), 85-96.
26.
Kaltenthaler E., Shackley P., Stevens K., Beverley C., Parry G. and Chilcott J.
(2002). A systematic review and economic evaluation of computerised
cognitive behaviour therapy for depression and anxiety. Health Technology
Assessment, 6(22).
27.
Shackley P., Slack R. and Michaels J. (2001). Vascular patients’ preferences
for local treatment: an application of conjoint analysis. Journal of Health
Services Research and Policy, 6(3), 151-157.
28.
O’Shea E., Stewart J., Donaldson C. and Shackley P. (2001). Eliciting
preferences for resource allocation in health care. Economic and Social
Review, 32(3), 217-238.
29.
Shackley P., Slack R., Booth A. and Michaels J. (2000). Is there a positive
volume-outcome relationship in peripheral vascular surgery? Results of a
systematic review. European Journal of Vascular and Endovascular Surgery,
20(4), 326-335.
30.
Michaels J., Brazier J., Palfreyman S., Shackley P. and Slack R. (2000). Cost
and outcome implications of the organisation of vascular services. Health
Technology Assessment, 4.
31.
Morgan A., Shackley P., Pickin M. and Brazier J. (2000). Quantifying patient
preferences for out-of-hours care. Journal of Health Services Research and
Policy, 5(4), 214-218.
32.
Shackley P. and Dixon S. (2000). Using contingent valuation to elicit public
preferences for water fluoridation. Applied Economics, 32(6), 777-787.
33.
Cairns J. and Shackley P. (1999). What price information? Modelling
threshold probabilities of fetal loss. Social Science and Medicine, 49, 823830.
34.
Shackley P., Slack R. and Michaels J. (1999). Costing vascular surgery: a
review of current reporting practice. Journal of Vascular Surgery, 30(4), 668678.
35.
Dixon S. and Shackley P. (1999). Estimating the benefits of community water
fluoridation using the willingness to pay technique: results of a pilot study.
Community Dentistry and Oral Epidemiology, 27, 124-129.
36.
Ryan M., McIntosh E. and Shackley P. (1998). Using conjoint analysis to elicit
the views of health service users: an application to the patient health card.
Health Expectations, 1(2), 117-129.
37.
Shackley P., Cairns J. and Gould I. (1997). Accelerated bacteriological
evaluation in the management of lower respiratory tract infection in general
practice. Journal of Antimicrobial Chemotherapy, 39, 663-666.
38.
Donaldson C., Shackley P. and Abdalla M. (1997). Using willingness to pay to
value close substitutes: carrier screening for cystic fibrosis revisited. Health
Economics, 6(2), 144-159.
39.
Donaldson C. and Shackley P. (1997). Does "process utility" exist? A case
study of willingness to pay for laparoscopic cholecystectomy. Social Science
and Medicine, 44(5), 699-707.
40.
Cairns J., Shackley P. and Hundley V. (1996). Decision making with respect to
diagnostic testing: a method of valuing the benefits of antenatal screening.
Medical Decision Making, 16(2), 161-168.
41.
Shackley P. and Cairns J. (1996). Evaluating the benefits of antenatal
screening: an alternative approach. Health Policy, 36(2), 103-115.
42.
Donaldson C., Shackley P., Abdalla M. and Miedzybrodzka Z. (1995)
Willingness to pay for antenatal carrier screening for cystic fibrosis. Health
Economics, 4(6), 439-452.
43.
Miedzybrodzka Z., Semper J., Shackley P., Abdalla M. and Donaldson C.
(1995). Stepwise or couple antenatal carrier screening for cystic fibrosis?
women's preferences and willingness to pay. Journal of Medical Genetics,
32, 282-283.
44.
Philips A, Wakeman A, Keatinge R, Williams ES, McGuire A, Shackley P.
(1994). Pre-natal Screening for Down’s Syndrome. Journal of Public Health,
16(1), 114-117.
45.
McGuire A and Shackley P. (1994) Authors reply: An economic appraisal of
alternative pre-natal screening programmes for Down’s syndrome. Journal
of Public Health Medicine, 16, 114-117.
46.
Miedzybrodzka Z., Shackley P., Donaldson C. and Abdalla M. (1994).
Counting the benefits of screening: a pilot study of willingness to pay for
cystic fibrosis carrier screening. Journal of Medical Screening, 1(2), 82-83.
47.
Cairns J. and Shackley P. (1994). Assessing value for money in medical
screening. Journal of Medical Screening, 1(1), 39-44.
48.
Shackley P. (1994). Market and Health – Reisman D. Health Econ 3(3), 207 –
207.
49.
Shackley P., McGuire A., Boyd P., Dennis J., Fitchett M., Kay J., Roche M.,
Wood P. (1993). An economic appraisal of alternative prenatal screening
programmes for Down's syndrome. Journal of Public Health Medicine, 15(2),
175-184.
5.7.2 Refereed Journals – in Print - Reviews
50.
Palfreyman S., Brazier J. and Shackley P. (2010). Assessing current health
related quality of life questionnaires administered to patients with venous
ulcers: can they be used in economic evaluations? Journal of Clinical Nursing,
19, 892-897.
51.
Shackley P. and Donaldson C. (2000). Willingness to pay for publicly-financed
health care: how should we use the numbers? Applied Economics, 32(15),
2015-2021.
52.
Ryan M., McIntosh E. and Shackley P. (1998). Methodological issues in the
application of conjoint analysis in health care. Health Economics, 7(4), 373378.
53.
Shackley P. (1996).
Economic evaluation of prenatal diagnosis: a
methodological review. Prenatal Diagnosis, 16(5), 389-395.
54.
Cairns J. and Shackley P. (1995). Health Economics - the dog in the manger?
Lancet, 346 (supplement), 10.
55.
Shackley P. and Ryan M. (1995). Involving consumers in health care decision
making. Health Care Analysis, 3(3), 196-204.
56.
Ryan M. and Shackley P. (1995). Assessing the benefits of health care: how
far should we go? Quality in Health Care, 4(3), 207-213.
57.
Shackley P. and Ryan M. (1994). What is the role of the consumer in health
care? Journal of Social Policy, 23(4), 517-541.
58.
Shackley P. and Healey A. (1993). Creating a market: an economic analysis of
the purchaser-provider model. Health Policy, 25(1,2), 153-168.
59.
Shackley P. and Donald S. (1993). Prevention in primary care: the annual
assessment of elderly people. Health Policy, 25(1,2), 51-62.
60.
Cairns J. and Shackley P. (1993). Sometimes sensitive, seldom specific: a
review of the economics of screening. Health Economics, 2(1), 43-53.
61.
Cairns J. and Shackley P. (1992). The contribution of economics to screening
in health care. European Journal of Public Health, 2(2), 105-112.